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Abstract Previous studies demonstrated that antigranulocyte colony-stimulating factor
autoantibody (GMAb) was consistently present in patients with autoimmune pulmonary alveolar
proteinosis (aPAP), and, thus, represented candidature as a reliable diagnostic marker.
However, our large cohort study suggested that the concentration of this antibody was not
correlated with disease severity in patients. We found that the κ/λ ratio of GMAb was
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358 T. Nei et al.λ-type IgG was significantly higher in severely affected patients than those in mildly affected
patients, but the proportion of κ-type was unchanged. The κ/λ ratio was significantly correlated
with both KL-6 and SP-D, which have been previously reported as disease severity markers. Thus,
the light chain isotype usage of GMAb may not only be associated with the severity of aPAP, but
may also represent a useful disease severity marker.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Detection of granulocyte macrophage-colony stimulating
factor (GM-CSF) autoantibody (GMAb) is known to be an
excellent test with almost 100% sensitivity and specificity for
the serological diagnosis of autoimmune pulmonary alveolar
proteinosis (aPAP), which comprises 90% of all acquired PAP
cases. This indicates its potential value in the routine
clinical diagnosis of the disease; however, the test has
neither approval nor commercial availability for clinical use
[1]. On the other hand, our previous report demonstrated
that serum GMAb levels were not correlated with the
degree of hypoxemia [2] (according to disease severity
score; partial pressure of oxygen in arterial blood, PaO2;
and alveolar–arterial oxygen difference, AaDO2), but were
moderately correlated with serum surfactant protein-A, -D,
Krebs von den Lungen (KL)-6, and carcinoembryonic antigen
(CEA) levels [1]. Because the autoantibodies were polyclonal,
thereby recognizing multiple target epitopes on GM-CSF
molecules with variable binding avidity, the loss of GM-CSF
bioactivity in the lungs of patientswith aPAPwas thought to be
affected not only by the concentration but also by multiple
properties of GMAb such as binding avidity, neutralizing
capacity, or targeting epitope. Thus, no characteristic
correlation has been demonstrated between the properties
of GMAb and the degree of hypoxemia.
Each B lymphocyte expresses only one isotype of light chain,
κ or λ, which remains fixed for the life of the B lymphocyte.
While immunoglobulin synthesis is matured and continually
stimulated, theλ chain immunoglobulin concentration reaches
a plateau by one year after birth and is maintained throughout
the child's life [3]. On the other hand, the concentration of
the κ chain, which increases gradually until 20 years of age,
reflects the concentration of immunoglobulins as a whole
[3,4]. The κ/λ ratio of immunoglobulin in normal adults ranges
from 0.85 to 1.86 [5,6], from which it then becomes divergent
in patients with monoclonal gammopathy or some autoimmune
diseases. Studies suggest a selective preference for either κ-
orλ-light chains in autoantibody formation, such as rheumatoid
factor (RF) [7,8], anti-cardiolipin antibodies [9], anti-neutrophil
antibodies [10], several thyroid-stimulating antibodies [11,12],
anti-lamin B antibody [13], and circulating immune complexes
in juvenile idiopathic arthritis [14]. Thus, measuring κ/λ ratios
in some autoantibodies may be useful to identify the state of
activation of B cells involved in some autoimmune diseases.
Studies suggest selective preference for either κ or λ chains in
autoantibody formation.
During a previous study on characterization of GMAb in
patients with aPAP in comparison to pharmaceutical immu-
noglobulin (IVIG), which was produced from pooled normal
sera of more than 1000 normal subjects, we measured con-
centrations, binding avidities, and κ/λ ratios of GMAb. Wenoticed that the κ/λ ratio was much higher for GMAb than for
whole IgG in both IVIG and aPAP groups, but it decreased as the
disease severity of aPAP increased. The aim of this studywas to
assess the potential use of the κ/λ ratio as a disease severity
marker in aPAP. In addition, we discuss the possibility that a
selective preference in light chain isotype usage might be
associated with the pathogenesis of aPAP.
2. Materials and methods
2.1. Subjects
Forty-six patients with aPAP were enrolled in this study. All
patients were diagnosed with PAP by computed tomography
findings and lung biopsy or bronchoalveolar lavage findings,
and diagnosis was confirmed by the existence of GM-CSF
autoantibodies in sera according to the diagnostic criteria
(http://www.pap-guide.jp/en/). The median age, gender,
proportion of symptomatic individuals, mean arterial blood
oxygen pressure, and mean percent vital capacity were
comparable to those in our previous large cohort study [2].
All serum and plasma samples were gathered in our
institution to measure the level of GM-CSF autoantibodies
after written informed consent to collect samples. All
participants provided written informed consent; minors
provided consent in accordance with the Declaration of
Helsinki. Healthy volunteers were also enrolled into the study
as healthy subjects (HS) after agreementwithwritten informed
consent. All patients with aPAP were categorized by disease
severity score (DSS) at enrollment, as previously described [2],
from least severe (DSS-1) to most severe (DSS-5).
2.2. Pharmaceutical immunoglobulin (IVIG)
Eight different batches of pharmaceutically-prepared im-
munoglobulin, Venoglobulin-IH™, were kindly provided by
Mitsubishi Pharma Corporation (Tokyo, Japan).
2.3. Enzyme-linked immunosorbent assay (ELISA)
2.3.1. Whole IgG
The serum concentration of whole IgG was measured by using
a human IgG ELISA quantitation kit (Bethyl, Montgomery, TX,
USA) according to the manufacturer's instructions.
2.4. GM-CSF autoantibody
Serum and culture medium GM-CSF autoantibody levels were
measured using direct ELISA as previously reported [15–17].
In brief, micro-ELISA plates (Maxisorp™ flat-bottom, clear,
96-well plates; Nunc, Roskilde, Denmark) were coated with
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cerevisiae (Leukine™, sarglamostim; Genzyme, Boston, MA,
USA) at 2 μg/ml with phosphate-buffered saline (PBS) at 4 °C
overnight. After washing with PBS containing 0.1% Tween™-T
(0.1% PBS-T) (MP Biomedicals, Solon, OH, USA), plates were
stabilized with blocking solution (Stabilcoat™, SurModics,
Eden Prairie, MN, USA) for 1 h at room temperature. Standard
human monoclonal GM-CSF autoantibodies with λ light chain
isotypes were kindly provided by Dr. Kenzo Takada (Evec Co.
Ltd., Sapporo, Japan). Standard GM-CSF autoantibody was
diluted in PBS containing 1% bovine serum albumin (1% BSA/
PBS) and was used as a standard for antibody measurement.
Serum and plasma samples were diluted into 1% BSA/PBS at a
3000-fold dilution, and a volume of 50 μl of prepared samples
and standardwas transferred to plates. After keeping plates at
room temperature for 1 h and washing with 0.1% PBS-T,
autoantibodies captured by rhGM-CSF were detected by
peroxidase-labeled anti-human Fcγ, Fcμ, or Fcα antibody
(Dako Corporation, Carpinteria, CA, USA). Afterwashing, color
was developed using tetramethylbenzidine (TMB) solution,
and the absorbance was measured at 450 nm.
2.5. Light chain assay
Based on the same ELISA method as above, peroxidase-
conjugated anti-human lambda light chain antibody (Bethyl)
was used for antibody detection. As the human monoclonal
antibody had λ-chains, we used this as the standard for
λ-type GMAb. The κ-type GMAb level was calculated by
subtraction of each λ-type GMAb level from the GMAb level.
2.6. Binding avidity
The rhGM-CSF (Leukine®) was dialyzed against PBS (pH 7.4)
and biotinylated using the NHS-PEO-biotin kit and monomeric
avidin kit (Pierce Biotech, Rockford, IL, USA) according to the
manufacturer's instructions. The purity of biotinylated GM-CSF
(bGM-CSF) was almost 100%. For estimation of binding avidity,
the serum GMAb concentration was fixed at 0.685 nM
(100 ng/ml) in every assay and was incubated with various
concentrations of bGM-CSF (0–1.25 nM) at 4 °C for 1 h and
then transferred into a 96-well plate, which was previously
coated with 1 μg/ml of anti-human IgG (Bethyl). The bound
bGM-CSF was reacted with streptavidin-peroxidase. Then, the
reactant was colored with TMB solution, and the OD (at
450 nm) was measured. Based on Lineweaver–Burk plots of
the concentration of bGM-CSF and OD values, the average
binding dissociation constant (Kd) was determined from the
concentration of bGM-CSF at 50% of the maximal OD value.
2.7. Statistical analysis
Numerical data were evaluated for a normal distribution
using Shapiro–Wilk tests and for equal variance using Levine
median tests. Parametric data are presented as means
(±SE), and non-parametric data are presented as medians
and ranges. Nonparametric data were compared with the
use of the Mann–Whitney U test (for two groups, non-
paired), or Wilcoxon signed-rank test (for two groups,
paired). Correlation coefficients were obtained using the
Spearman's correlation method. All tests were two-sided,and P-values b 0.05 were considered to indicate statistical
significance. Data were analyzed by using JMP (8.0.1)
software (SAS, Cary, NC). Figures were made by Stat View
(v. 5.0) (SAS, Cary, NC) and Microsoft Power Point (Microsoft,
Seattle, WA).
3. Results
3.1. Demographic features of the study subjects
Forty-six patients with positive serumGMAb and pathologically-
proven PAP were enrolled in this study. The demographic
features, including age, gender, symptoms, arterial blood gas
analysis, pulmonary function tests (percent vital capacity, %VC;
percent forced expiratory volume in one second, %FEV1.0, and,
percent diffusing capacity for carbon monoxide, %DLCO), DSS,
and serummarkers (KL-6 and SP-D) (Table 1) in this group were
similar to those of the 223 participants in our previous cross-
sectional, large cohort study [2], indicating that patients in
the present study had similar backgrounds to the general
demographic features of aPAP in Japan. The median PaO2 was
67.5 mm Hg, and the numbers of patients in each DSS were 11,
6, 18, 8, and 3 for DSS 1 to 5, respectively, with amean score of
2.7 ± 1.2.
3.2. Association of GMAb concentrations and binding
avidities with disease severity
To assess the correlation of GMAb properties with disease
severity, we first investigated the concentration and its
proportion to whole IgG in the sera of patients with aPAP as
compared to IVIG. As shown in Fig. 1A, the concentrations of
IgG isotype GMAb were higher than 3.0 μg/ml in all patients,
with a mean value of 46.7 ± 34.1 μg/ml, whereas the levels
were less than 3.0 μg/ml for IVIG (2.21 ± 0.38 μg/ml, n = 8).
The mean percentage of GMAb per total IgG was 21.7-fold
higher in aPAP than in IVIG (P b 0.0001, Fig. 1B). “Both
the concentrations and the percentages did not correlate
with the degree of hypoxemia (i.e., PaO2, AaDO2, and DSS)
(Supplemental Table 1).
Thus, we confirmed our previous results in a large cohort
study [2] using a different set of samples in this study.
Then, we evaluated the correlation of binding avidity with
disease severity. As the concentration of GMAb increased,
the avidity to recombinant human GM-CSF was remarkably
variable among the patients, with a mean value of 0.48 nM
(Fig. 1C). The mean avidity value was higher in IVIG than
those in aPAP patients (P b 0.05). As the binding avidity of
antibodies is generally thought to reflect the frequency and
intensity of ligand stimulation, we considered that the avidity
of GMAb in aPAP patients might be associated with disease
severity. However, the avidity correlated with none of the
parameters regarding the degree of hypoxemia (Supplemental
Table 1).
Our previous study demonstrated that serum biomarkers
KL-6, SP-D, and pulmonary functions correlated with disease
severity [2]. Similarly, we confirmed these results using the
present data set. Both KL-6 and SP-D were correlated
moderately to strongly with the degree of hypoxemia as
shown in Supplemental Table 1. Of pulmonary function data,
percent vital capacity (%VC) and percent diffusing capacity
Table 1 Demographic data of study subjects.
Characteristics n % Mean ± SD
(minimum–maximum)
Number 46
Age (years) 50.5 ± 14.9 (16–85)
Gender
Male 29 63
Female 17 37
Clinical symptoms
None 12 26
Dyspnea on effort 25 54
Cough 18 39
Others 3 7
Arterial blood gas analysis
PaO2 (Torr) 46 69.3 ± 13.8 (40.6–99.7)
PaCO2 (Torr) 46 38.4 ± 4.3 (28.6–47.5)
AaDO2 (Torr)
a 46 33.1 ± 14.7 (2.6–60.2)
Pulmonary function test
%VC 38 90.4 ± 14.9 (55.6–116.9)
%FEV1.0 35 83.3 ± 10.3 (67.8–126.5)
%DLCO 30 61.2 ± 23.4 (8.4–99.7)
Disease severity score 46 2.5 ± 1.1 (1–5)
Serum markers
KL-6 (U/ml) 45 4431 ± 4707 (147–23,000)
SP-D (ng/ml) 45 184.4 ± 129.4 (17.3–498)
Definition of abbreviations: AaDO2 = alveolar–arterial oxygen
difference; GM-CSF = granulocyte/macrophage-colony stimulating
factor; NS = not significant.
PB; barometric pressure measured by local observatories, PH20;
partial pressure of water vapor in inspired air (assumed to be
47 Torr), FIO2; fractional concentration of oxygen in dry gas
(assumed to be 0.21), PaCO2; partial pressure of arterial CO2
measured in arterial blood, R; respiratory quotient (assumed
to be 0.8), PaO2; partial pressure of arterial oxygen measured in
arterial blood.
The serum concentration of GM-CSF autoantibody with λ isotype
(Igλ-GMAb) was measured by GMAb ELISA(2) using recombinant
GM-CSF (Leukine™, Immunex Co., WA) for antigen capture and
peroxidase labeled anti-lambda antibody (Bethyl Laboratories Inc.,
Montgomery, TX) for detecting antibody. The serum concentration
of whole GM-CSF autoantibody was measured using peroxidase
labeled anti-whole immunoglobulin antibody as the detecting
antibody. For the standard, monoclonal human GM-CSF antibody
(kindly provided from Dr. Kenzo Takada, Evec Co. Ltd., Sapporo,
Japan) with lambda isotype was used. Kappa/lambda ratio was
calculated by the following equation.
kappa/lambda ratio = (whole immunoglobulin concentration −
Igλ-GMAb) / Igλ-GMAb.
a Calculated using the following equation: AaDO2 = (PB − PH20) ×
FIO2 / R + {PaCO2 × FIO2 × (1 − R) / R} − PaO2.
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lations with the degree of hypoxemia.3.3. Correlation between κ/λ ratios of GMAb and
disease severity
Another important property of GMAb that might affect the
blocking capacity of GM-CSF bioactivity is the binding of
paratopes, consisting of some parts of variable regions in
both light and heavy chains. As the light chain κ/λ ratio isknown to change in some autoimmune diseases, we focused
on the ratio of GMAb in aPAP patients as compared to IVIG.
The mean κ/λ ratio in total IgG was similar between aPAP
patients and IVIG with values of 1.23 ± 0.60 and 1.41 ± 0.27,
respectively (Fig. 2A), which were comparable to the data in
normal subjects reported previously [5,6]. On the other
hand, the mean κ/λ ratio of GMAb was higher in IVIG (3.60 ±
0.71) than in aPAP patients (2.12 ± 1.37) (P b 0.01, Fig. 2B).
The κ/λ ratio of GMAb was strikingly higher in both aPAP
patients and IVIG than the κ/λ ratio of the corresponding
total IgG (Fig. 2C, P b 0.001 and P b 0.05, respectively). The
κ/λ ratio of GMAb in patients was highly variable, ranging
from 0.002 to 5.75 as compared with total IgG (Fig. 2C),
suggesting that GMAb-producing B cells or plasma cells are
polyclonally activated. The κ/λ ratio of GMAbwas significantly
higher than the ratio of the total IgG (P b 0.001).
When we evaluated the correlation between the κ/λ
ratio and the disease severity parameters in aPAP patients,
we found that the κ/λ ratio was moderately correlated
with PaO2 (Fig. 3A, ρ = 0.411, P b 0.01) and inversely and
moderately correlated with both AaDO2 (Fig. 3B, ρ = −0.484,
P b 0.001) and DSS (Fig. 3C, ρ = −0.378, P b 0.01). When the
κ-type or λ-type GMAbs were compared between patients
with mild and severe aPAP (PaO2 higher and lower than
67.5 mm Hg, respectively), the κ/λ ratio of GMAb was
significantly higher in the former group than the latter
(Fig. 4A, P b 0.05). Interestingly, the proportion of λ-type
GMAb per whole λ-type IgG was significantly higher in the
latter group than the former, whereas the proportion of
κ-type GMAb per total κ-type IgG was equal between the two
groups (Figs. 4B (P b 0.05) and 4C). This result suggested that
λ-type GMAb predominantly increased in the severe aPAP.
3.4. Correlation between κ/λ ratio of GMAb and
other parameters
As both serum markers and pulmonary functions are widely
accepted as disease severity parameters, we evaluated
whether serum κ/λ ratio correlated with these parameters.
The κ/λ ratio weakly to moderately correlated with KL-6
(ρ = −0.297, P b 0.05) and SP-D (ρ = −0.360, P b 0.05), but
not with %VC and %DLCO (Supplemental Table 2). Neither the
concentrations nor binding avidities of GMAb correlated with
the disease severity or the κ/λ ratio of GMAb (Supplemental
Table 2). Then, the patients were classified into two groups;
group 1: patients with high binding avidity less than 0.24 nM
(the mean + 2SD for IVIG) and group 2: patients with low
binding avidity over 0.24 nM. In group 1, the serum κ/λ ratio
was similar between severe (b67.5 mm Hg in PaO2) and mild
(≧67.5 mm Hg in PaO2) disease, whereas, in group 2, the κ/λ
ratio was higher in mild patients (2.85 + 1.60) than severe
(1.43 + 1.08) patients (P b 0.05, Fig. 4D). Thus, the association
of serum κ/λ ratio with disease severity was obvious in patients
with low avidity GMAb but not in patients with high avidity
GMAb.
4. Discussion
In this study, we demonstrated that the light-chain ratio (κ/λ
ratio) of GMAb in patients with aPAP and IVIG was higher than
total IgG, and the κ/λ ratio was significantly correlated with
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Figure 1 (A) Comparison of GMAb between patients with aPAP (n = 46) and IVIG preparations (n = 8). GMAb concentrations were
significantly higher in aPAP patients than IVIG preparations (P b 0.0001, Mann–Whitney U-test). (B) Comparison of the percent GMAb per
total IgG betweenpatientswith aPAP (n = 46) and IVIG preparations (n = 8). PercentGMAb per total IgGwas significantly higher in the aPAP
group than IVIG (P b 0.0001, Mann–Whitney U-test). (C) Comparison of the binding avidity of GMAb between patients with aPAP and IVIG
preparations. The binding avidity of GMAb was significantly higher in IVIG than that of the aPAP group (P b 0.05, Mann–Whitney U-test).
0
1
2
3
4
5
6
GMAb total IgG
P<0.001
κ
/λ
 
ra
tio
P<0.05
GMAb total IgG
aPAP IVIG
0
1
2
3
aPAP IVIG
To
ta
l I
gG
 κ
/λ
 
ra
tio
NS
0
2
4
6
aPAP IVIG
G
M
Ab
 κ
/λ
 
ra
tio
P<0.01
A B
C
Figure 2 Comparison of the κ/λ ratio of total IgG (A) and
GMAb (B) between aPAP patients and IVIG preparations. The
mean κ/λ ratio in total IgG was similar between aPAP patients
and IVIG preparations, whereas the κ/λ ratio for GMAbs was
significantly higher in IVIG as compared to aPAP patients
(P b 0.05, Mann–Whitney U-test). (C) Comparison of the κ/λ
ratio as compared between GMAb and total IgG for each
individual sample (gray lines) and the average (black line) in
aPAP patients (left panel) and IVIG preparations (right panel).
For both aPAP patients and IVIG preparations, the κ/λ ratio of
GMAb was significantly higher than total IgG (P b 0.001 and
P b 0.05, respectively, Wilcoxon signed-rank test).
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Figure 3 Correlations between the κ/λ ratio of GMAb and
clinical parameters: (A) PaO2 and (B) AaDO2. Each combination was
highly correlated (P b 0.01, R = 0.411; P b 0.001, R = −0.484,
respectively). All data were evaluated by using Spearman's rank
correlation coefficient. (C) The κ/λ ratio as a function of DSS. With
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362 T. Nei et al.disease severity (i.e., the degree of hypoxemia). As previous
reports and the present data indicated that the serum
concentration of GMAb and the binding avidity of GMAb had
no correlation with disease severity [2,18,19], the present
study is the first to suggest that the light chain isotype usage in
GMAb might be associated with disease severity.
GMAb has been widely accepted as the causative
pathogen of aPAP [1,20] because GMAb showed consistently
high concentrations in both the lungs and blood with strong
binding avidities to GM-CSF, and its injection is known to
reproduce PAP in nonhuman primates [21]. In the late 90s,
Svenson et al. demonstrated that a high avidity but low
concentration of GMAb was ubiquitously present in every
batch of pharmaceutically-prepared immunoglobulin (IVIG),
and such antibodies neutralized GM-CSF bioactivity [22].
This suggested the presence of GMAb in the sera of normal
subjects because IVIG is the product from pooled sera of
normal donors. More recently, we confirmed that a lowconcentration of GMAb was ubiquitously present in the sera
of normal subjects, showing similar biological properties in
aPAP [23]. In this regard, we first report the difference in
properties of GMAb between IVIG and aPAP patients: the κ/λ
ratio of GMAb is significantly higher in IVIG than that in aPAP
patients.
Considering that GMAbs consistently, but not exceedingly,
exist in the sera of healthy subjects, membrane GMAb+ B cell
clones seemed to be stimulated by intrinsic GM-CSF in healthy
subjects. As κ-chain was predominant in GMAbs in IVIG, it is
likely that some membrane GMAb+ B cell clones in healthy
subjects underwent class switching without undergoing
apoptosis or receptor editing. On the other hand, increased
λ-type GMAb in severely affected aPAP patients might be due
to the selective expansion of λ-type membrane GMAb+ B
clones in the peripheral lymphatic tissues.
Recently, Wang et al. investigated 19 monoclonal anti-
bodies against GM-CSF established from six patients with aPAP
363κ/λ ratio of GM-CSF autoantibodyand demonstrated that the affinity of each antibody corre-
lated with the neutralizing capacity [24]. In this regard, it is
plausible that the binding avidity might be associated with the
κ/λ ratio, and thus, correlated with disease severity through
the neutralizing capacity. However, our present data ex-
cluded this possibility (i.e., the binding avidity correlatedwith
neither the κ/λ ratio nor the disease severity).
In our previous reports, the correlation coefficients
between the disease severity and the serum markers of LDH,
CEA, SP-A, KL-6, and SP-D were 0.29–0.53 [2]. The correlation
coefficient of the κ/λ ratio with the disease severity
(ρ = −0.378) was comparable with the coefficients described
above. It is of interest for future studies to assess how closely
the κ/λ ratio of GMAb correlates with the longitudinal change
of disease severity and how precisely the κ/λ ratio predicts
the prognosis of aPAP.
In patients with aPAP, the κ/λ ratio of GMAbwas remarkably
variable compared with total IgG. The variability may be
partially due to the frequency of antigen stimulation, receptor
editing, or clonal expansion in the secondary lymphatic organs.
As λ chain usage was shown to be correlated with disease
severity in this study, it is plausible to consider that some
critical sequences for binding with GM-CSF are coded in the λ
chain of GMAb. Moreover, as a light chain binds antigens with a
corresponding heavy chain, such critical sequences may be also
coded in heavy chains, especially in CDR3 regions, which are
known to bemajor paratopes. Thesemolecular issues remain to
be investigated in future studies.
5. Conclusion
Investigation of the light-chain isotype ratio of GMAb in patients
with aPAP and healthy subjects revealed that the κ chain is
predominant in general, but the proportion of the λ chain
increases as disease severity increases in patients with aPAP.
This study may provide an important clue as to the mechanism
for the production of GMAb. For future study, it is intriguing to
investigate whether the disease progression is associated with
the serum κ/λ ratio retrospectively and prospectively.
Conflict of interest statement
None of the authors have a financial relationship with a
commercial entity with an interest in the subject of this
manuscript.
Acknowledgments
The authors thank Jun Takizawa, Takuji Suzuki, Kiyoko
Akagawa, and Teruhito Yasui for valuable discussions, Bruce
C. Trapnell for valuable criticism, and Marie Mori for technical
help. For collecting patient samples and information, the
authors thank Koichiro Tatsumi, Yoshiko Tsuchihashi, Akira
Fujita, Keiichi Akasaka, Toshio Ichiwata, and Yokoh Shibata.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.clim.2013.10.002.References
[1] T. Kitamura, K. Uchida, N. Tanaka, T. Tsuchiya, J. Watanabe,
Y. Yamada, K. Hanaoka, J.F. Seymour, O.D. Schoch, I. Doyle,
Y. Inoue, M. Sakatani, S. Kudoh, A. Azuma, T. Nukiwa, T.
Tomita, M. Katagiri, A. Fujita, A. Kurashima, S. Kanegasaki, K.
Nakata, Serological diagnosis of idiopathic pulmonary alveolar
proteinosis, Am. J. Respir. Crit. Care Med. 162 (2000) 658–662.
[2] Y. Inoue, B.C. Trapnell, R. Tazawa, T. Arai, T. Takada, N. Hizawa,
Y. Kasahara, K. Tatsumi, M. Hojo, T. Ichiwata, N. Tanaka, E.
Yamaguchi, R. Eda, K. Oishi, Y. Tsuchihashi, C. Kaneko, T. Nukiwa,
M. Sakatani, J.P. Krischer, K. Nakata, J.C.o.t.R.L.D Consortium,
Characteristics of a large cohort of patients with autoimmune
pulmonary alveolar proteinosis in Japan, Am. J. Respir. Crit. Care
Med. 177 (2008) 752–762.
[3] A.L. Renckens, M.J. Jansen, P.J. van Munster, C.M. Weemaes,
J.A. Bakkeren, Nephelometry of the kappa/lambda light-chain
ratio in serum of normal and diseased children, Clin. Chem. 32
(1986) 2147–2149.
[4] K.R. Herkner, H. Salzer, A. Böck, A. Mühl, T. Tsaka, H. Steger,
A. Pollak, C. Schatten, W. Popp, V. Huber-Spitzy, Pediatric and
perinatal reference intervals for immunoglobulin light chains
kappa and lambda, Clin. Chem. 38 (1992) 548–550.
[5] K. Sølling, Normal values for free light chains in serum different
age groups, Scand. J. Clin. Lab. Invest. 37 (1977) 21–25.
[6] S. Barandun, A. Morell, F. Skvaril, A. Oberdorfer, Deficiency of
kappa- or lambda-type immunoglobulins, Blood 47 (1976) 79–89.
[7] I. Ezaki, M. Shingu, M. Hashimoto, T. Isayama, J. Tohmatsu, H.
Kanda, M. Nobunaga, T. Watanabe, Analysis of the genes
encoding the variable regions of human IgG rheumatoid factor,
J. Rheumatol. 21 (1994) 2005–2010.
[8] R.W. Ermel, T.P. Kenny, A. Wong, A. Solomon, P.P. Chen, D.L.
Robbins, Preferential utilization of a novel V lambda 3 gene in
monoclonal rheumatoid factors derived from the synovial cells
of rheumatoid arthritis patients, Arthritis Rheum. 37 (1994)
860–868.
[9] A. Haraldsson, H.A. Tiddens, T. Fiselier, J.A. Bakkeren, C.M.
Weemaes, Altered immunoglobulin concentrations and light
chain ratios in juvenile onset mixed connective tissue disease,
Clin. Rheumatol. 14 (1995) 51–54.
[10] K.A. Shastri, B.M. O'Connor, G.L. Logue, D.S. Shimm, P.K.
Rustagi, Light chain composition of serum granulocyte binding
immunoglobulins, Am. J. Hematol. 37 (1991) 167–172.
[11] R.C. Williams, N.J. Marshall, K. Kilpatrick, J. Montano, P.M.
Brickell, M. Goodall, P.A. Ealey, B. Shine, A.P. Weetman, R.K.
Craig, Kappa/lambda immunoglobulin distribution in Graves'
thyroid-stimulating antibodies. Simultaneous analysis of C lambda
gene polymorphisms, J. Clin. Invest. 82 (1988) 1306–1312.
[12] J. Knight, P. Laing, A. Knight, D. Adams, N. Ling, Thyroid-
stimulating autoantibodies usually contain only lambda-light
chains: evidence for the “forbidden clone” theory, J. Clin.
Endocrinol. Metab. 62 (1986) 342–347.
[13] W.H. Reeves, S.A. Ali, Preferential use of lambda L chain in
lamin B autoantibodies, J. Immunol. 143 (1989) 3614–3618.
[14] J.M. Low, A.K. Chauhan, T.L. Moore, Abnormal kappa:lambda
light chain ratio in circulating immune complexes as a marker
for B cell activity in juvenile idiopathic arthritis, Scand. J.
Immunol. 65 (2007) 76–83.
[15] K. Uchida, K. Nakata, B.C. Trapnell, T. Terakawa, E. Hamano,
A. Mikami, I. Matsushita, J.F. Seymour, M. Oh-Eda, I. Ishige, Y.
Eishi, T. Kitamura, Y. Yamada, K. Hanaoka, N. Keicho, High-
affinity autoantibodies specifically eliminate granulocyte-
macrophage colony-stimulating factor activity in the lungs of
patients with idiopathic pulmonary alveolar proteinosis, Blood
103 (2004) 1089–1098.
[16] S. Urano, C. Kaneko, T. Nei, N. Motoi, R. Tazawa, M. Watanabe,
M. Tomita, T. Adachi, H. Kanazawa, K. Nakata, A cell-free assay
to estimate the neutralizing capacity of granulocyte-macrophage
364 T. Nei et al.colony-stimulating factor autoantibodies, J. Immunol. Methods
360 (2010) 141–148.
[17] T. Nei, S. Urano, N. Motoi, J. Takizawa, C. Kaneko, H.
Kanazawa, R. Tazawa, K. Nakagaki, K.S. Akagawa, K. Akasaka,
T. Ichiwata, A. Azuma, K. Nakata, IgM-type GM-CSF autoantibody
is etiologically a bystander but associated with IgG-type
autoantibody production in autoimmune pulmonary alveolar
proteinosis, Am. J. Physiol. Lung Cell. Mol. Physiol. 302 (2012)
L959–L964.
[18] F. Bonella, P.C. Bauer, M. Griese, S. Ohshimo, J. Guzman, U.
Costabel, Pulmonary alveolar proteinosis: new insights from a
single-center cohort of 70 patients, Respir. Med. 105 (2011)
1908–1916.
[19] Y. Inoue, K. Nakata, T. Arai, R. Tazawa, E. Hamano, T. Nukiwa,
K. Kudo, N. Keicho, N. Hizawa, E. Yamaguchi, R. Eda, K. Oishi,
Y. Maeda, Y. Koreeda, N. Kodo, M. Sakatani, Epidemiological and
clinical features of idiopathic pulmonary alveolar proteinosis in
Japan, Respirology 11 (2006) S55–S60(Suppl.).
[20] T. Kitamura, N. Tanaka, J. Watanabe, Uchida, S. Kanegasaki, Y.
Yamada, K. Nakata, Idiopathic pulmonary alveolar proteinosis as
an autoimmune disease with neutralizing antibody against
granulocyte/macrophage colony-stimulating factor, J. Exp.
Med. 190 (1999) 875–880.[21] T. Sakagami, D. Beck, K. Uchida, T. Suzuki, B.C. Carey, K.
Nakata, G. Keller, R.E. Wood, S.E. Wert, M. Ikegami, J.A.
Whitsett, M. Luisetti, S. Davies, J.P. Krischer, A. Brody, F.
Ryckman, B.C. Trapnell, Patient-derived granulocyte/
macrophage colony-stimulating factor autoantibodies re-
produce pulmonary alveolar proteinosis in nonhuman primates,
Am. J. Respir. Crit. Care Med. 182 (2010) 49–61.
[22] M. Svenson, M.B. Hansen, C. Ross, M. Diamant, K. Rieneck, H.
Nielsen, K. Bendtzen, Antibody to granulocyte-macrophage
colony-stimulating factor is a dominant anti-cytokine activity
in human IgG preparations, Blood 91 (1998) 2054–2061.
[23] K. Uchida, K. Nakata, T. Suzuki, M. Luisetti, M. Watanabe, D.E.
Koch, C.A. Stevens, D.C. Beck, L.A. Denson, B.C. Carey, N.
Keicho, J.P. Krischer, Y. Yamada, B.C. Trapnell, Granulocyte/
macrophage-colony-stimulating factor autoantibodies and
myeloid cell immune functions in healthy subjects, Blood 113
(2009) 2547–2556.
[24] Y. Wang, C.A. Thomson, L.L. Allan, L.M. Jackson, M. Olson, T.R.
Hercus, T.L. Nero, A. Turner, M.W. Parker, A.L. Lopez, T.K.
Waddell, G.P. Anderson, J.A. Hamilton, J.W. Schrader, Char-
acterization of pathogenic human monoclonal autoantibodies
against GM-CSF, Proc. Natl. Acad. Sci. U. S. A. 110 (2013)
7832–7837.
